These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dosage form design and development. Allen LV Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798 [TBL] [Abstract][Full Text] [Related]
5. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Chen ML Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051 [TBL] [Abstract][Full Text] [Related]
6. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation. Moribe K; Tozuka Y; Yamamoto K Adv Drug Deliv Rev; 2008 Feb; 60(3):328-38. PubMed ID: 18006109 [TBL] [Abstract][Full Text] [Related]
7. Advanced microscopy techniques to assess solid-state properties of inhalation medicines. Shur J; Price R Adv Drug Deliv Rev; 2012 Mar; 64(4):369-82. PubMed ID: 22120022 [TBL] [Abstract][Full Text] [Related]
8. Supercritical fluid technologies: an innovative approach for manipulating the solid-state of pharmaceuticals. Pasquali I; Bettini R; Giordano F Adv Drug Deliv Rev; 2008 Feb; 60(3):399-410. PubMed ID: 17964684 [TBL] [Abstract][Full Text] [Related]
9. Magnetic marker monitoring: high resolution real-time tracking of oral solid dosage forms in the gastrointestinal tract. Weitschies W; Blume H; Mönnikes H Eur J Pharm Biopharm; 2010 Jan; 74(1):93-101. PubMed ID: 19619649 [TBL] [Abstract][Full Text] [Related]
10. Approaches for the development of solid and semi-solid lipid-based formulations. Jannin V; Musakhanian J; Marchaud D Adv Drug Deliv Rev; 2008 Mar; 60(6):734-46. PubMed ID: 18045728 [TBL] [Abstract][Full Text] [Related]
11. High-amylose carboxymethyl starch matrices for oral sustained drug-release: in vitro and in vivo evaluation. Nabais T; Brouillet F; Kyriacos S; Mroueh M; Amores da Silva P; Bataille B; Chebli C; Cartilier L Eur J Pharm Biopharm; 2007 Mar; 65(3):371-8. PubMed ID: 17275270 [TBL] [Abstract][Full Text] [Related]
12. [The importance of micronization in the design of dosage forms II. Pharmaceutical technological considerations]. Antal I Acta Pharm Hung; 2006; 76(3):149-54. PubMed ID: 17094663 [TBL] [Abstract][Full Text] [Related]
13. [Physical ageing of amorphous polymeric excipients III. The possible consequences of ageing]. Zelkó R; Kiss D Acta Pharm Hung; 2006; 76(2):105-13. PubMed ID: 17094669 [TBL] [Abstract][Full Text] [Related]
14. Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms. Siepmann J; Siepmann F; Florence AT Int J Pharm; 2006 May; 314(2):101-19. PubMed ID: 16647231 [TBL] [Abstract][Full Text] [Related]
15. The "bubble point" for validation of drug release or simulated absorption tests for ointments. Realdon N; Tagliaboschi A; Perin F; Ragazzi E Pharmazie; 2005 Dec; 60(12):910-6. PubMed ID: 16398267 [TBL] [Abstract][Full Text] [Related]
16. Microwave generated solid dispersions containing Ibuprofen. Moneghini M; Bellich B; Baxa P; Princivalle F Int J Pharm; 2008 Sep; 361(1-2):125-30. PubMed ID: 18573321 [TBL] [Abstract][Full Text] [Related]
17. [Surface active agents in drug forms and biological systems]. Eros I Acta Pharm Hung; 2005; 75(2):59-68. PubMed ID: 16318230 [TBL] [Abstract][Full Text] [Related]
18. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. Prabhu S; Ortega M; Ma C Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087 [TBL] [Abstract][Full Text] [Related]
19. Crystal polymorphism in chemical process development. Lee AY; Erdemir D; Myerson AS Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619 [TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical applications of AC biosusceptometry. Corá LA; Américo MF; Romeiro FG; Oliveira RB; Miranda JR Eur J Pharm Biopharm; 2010 Jan; 74(1):67-77. PubMed ID: 19482083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]